CTC enumeration and characterization has predictive and prognostic implications in patients with metastatic breast cancer treated with exemestane plus the mTOR inhibitor everolimus

被引：0
|
作者：
Agelaki, Sofia [1 ,2 ]
Mavroudis, Dimitris [1 ,2 ]
Spiliotaki, Maria [2 ]
Politaki, Eleni [2 ]
Papadaki, Maria A. [2 ]
Apostolaki, Stella [2 ]
Nikolaou, Christos [1 ]
Georgoulias, Vassilis [1 ,2 ]
机构：
[1] Univ Hosp Heraklion, Iraklion, Greece
[2] Univ Crete, Sch Med, Lab Tumor Cell Biol, Rethimnon, Greece
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-01-13
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Erratum to: Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer
    Vakaramoko Diaby
    Georges Adunlin
    Simon B. Zeichner
    Kiran Avancha
    Gilberto Lopes
    Stefan Gluck
    Alberto J. Montero
    Breast Cancer Research and Treatment, 2014, 147 : 443 - 443
  • [22] Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
    Wolpin, Brian M.
    Hezel, Aram F.
    Abrams, Thomas
    Blaszkowsky, Lawrence S.
    Meyerhardt, Jeffrey A.
    Chan, Jennifer A.
    Enzinger, Peter C.
    Allen, Brittany
    Clark, Jeffrey W.
    Ryan, David P.
    Fuchs, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (02) : 193 - 198
  • [23] Everolimus and exemestane for the treatment of metastatic hormone receptor-positive breast cancer patients previously treated with CDK4/6 inhibitor based therapies.
    Cook, Madeline
    Al Rabadi, Luai
    Mitri, Zahi Ibrahim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] A Phase Ib Trial of Erlotinib, an EGFR Inhibitor, and Everolimus (RAD001), an mTOR Inhibitor, in Patients with Metastatic Breast Cancer.
    Mayer, I. A.
    Means-Powell, J.
    Shyr, Y.
    Arteaga, C. L.
    CANCER RESEARCH, 2009, 69 (24) : 677S - 677S
  • [25] Everolimus exposure and early metabolic response as predictors for treatment outcomes in breast cancer patients treated with everolimus and exemestane.
    Willemsen, Annelieke
    de Geus-Oei, Lioe-Fee
    De Boer, Maaike
    Tol, Jolien
    Kamm, Yvonne
    De Jong, Paul C.
    Vos, Allert Henrik
    de Groot, Jan Willem
    Mulder, Sasja F.
    Aarntzen, Erik H. J. G.
    Gerritsen, Winald R.
    Van Herpen, Carla M. L.
    Van Erp, Nielka P.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane
    Krasniqi, Eriseld
    Barchiesi, Giacomo
    Mazzotta, Marco
    Pizzuti, Laura
    Villa, Alice
    Barba, Maddalena
    Vici, Patrizia
    MEDICINE, 2020, 99 (31)
  • [27] mTOR inhibitor-associated stomatitis (mIAS) in three patients with cancer treated with everolimus
    Kalogirou, Eleni-Marina
    Tosios, Konstantinos I.
    Piperi, Evangelia P.
    Sklavounou, Alexandra
    ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, 2015, 119 (01): : E13 - E19
  • [28] Prognostic and predictive factors of eribulin in patients with heavily pre-treated metastatic breast cancer
    Chen, Pei-Hsin
    Yeh, Dah-Cherng
    Tung, Heng-Hsin
    Lin, Chin-Yao
    MEDICINE, 2021, 100 (47)
  • [29] Efficacy of Exemestane after Nonsteroidal Aromatase Inhibitor Use in Metastatic Breast Cancer Patients
    Kim, Sun Hye
    Park, In Hae
    Lee, Hyewon
    Lee, Keun Seok
    Nam, Byung-Ho
    Ro, Jungsil
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (03) : 979 - 983
  • [30] Fulvestrant versus everolimus plus exemestane for patients with metastatic breast cancer resistant to aromatase inhibitors: Clinical experience from real world.
    Li, Yi
    Xie, Yizhao
    Zhao, Yannan
    Hu, Xi-Chun
    Zhang, Jian
    Chen, Shen
    Gong, Chengcheng
    Zhang, Sheng
    Wang, Leiping
    Wang, Biyun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345